Garsorasib
| CAS No. | 2559761-14-5 | Cat. No. | BCP49682 |
| Name | Garsorasib | ||
| Synonyms | |||
| Formula | C32H32F2N8O2 | M. Wt | 598.65 |
| Description | Garsorasib is an orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, garsorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis. | ||
| Pathways | GPCR/G Protein | ||
| Targets | Ras/Rho | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.